OPKO Health Inc
OPK1.300USD
-0.010-0.76%
終値 12/24, 13:00（ET）15分遅れの株価
999.31M時価総額
損失額直近12ヶ月PER
詳細情報 OPKO Health Inc 企業名
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
OPKO Health Incの企業情報
企業コードOPK
会社名OPKO Health Inc
上場日Nov 02, 1995
最高経営責任者「CEO」Cruz (Tony F)
従業員数2997
証券種類Ordinary Share
決算期末Nov 02
本社所在地- -
都市- -
証券取引所NASDAQ OMX - NASDAQ BASIC
国- -
郵便番号- -
電話番号- -
ウェブサイト- -
企業コードOPK
上場日Nov 02, 1995
最高経営責任者「CEO」Cruz (Tony F)
OPKO Health Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Dr. Roger J. Medel, M.D.
Dr. Roger J. Medel, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
地域別USD
会社名
収益
比率
United States
114.88M
73.26%
Chile
16.00M
15.83%
Ireland
11.74M
11.61%
Spain
6.72M
6.65%
Mexico
6.30M
6.23%
他の
-54.55M
-13.59%
事業別
地域別
事業別USD
会社名
収益
比率
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
Frost Gamma Investments Trust
28.98%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.88%
Hsiao (Jane H)
4.32%
他の
50.34%
株主統計
株主統計
比率
Frost Gamma Investments Trust
28.98%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.88%
Hsiao (Jane H)
4.32%
他の
50.34%
種類
株主統計
比率
Corporation
38.14%
Investment Advisor
12.40%
Individual Investor
10.57%
Hedge Fund
7.37%
Investment Advisor/Hedge Fund
5.49%
Research Firm
0.48%
Bank and Trust
0.21%
Pension Fund
0.14%
Family Office
0.05%
他の
25.15%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
457
208.31M
27.13%
-63.18M
2025Q2
472
618.23M
77.88%
-578.48K
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
2023Q2
502
536.53M
70.13%
+25.42M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Frost Gamma Investments Trust
220.16M
27.74%
+360.00K
+0.16%
Sep 30, 2025
Rubric Capital Management LP
47.79M
6.02%
-915.40K
-1.88%
Jun 30, 2025
Holbrook (Bruce C)
40.38M
5.09%
--
--
Feb 24, 2025
The Vanguard Group, Inc.
38.16M
4.81%
+8.74M
+29.70%
Jun 30, 2025
Hsiao (Jane H)
33.13M
4.17%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.8%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
28.22M
3.55%
+3.45M
+13.93%
Jun 30, 2025
GJN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
Geode Capital Management, L.L.C.
10.42M
1.31%
+2.00M
+23.68%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
Invesco NASDAQ Future Gen 200 ETF
0.53%
State Street SPDR S&P Health Care Services ETF
0.46%
VanEck Israel ETF
0.14%
Humankind US Stock ETF
0.1%
iShares U.S. Healthcare Providers ETF
0.1%
Goldman Sachs Innovate Equity ETF
0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
詳細を見る
Invesco NASDAQ Future Gen 200 ETF
比率0.53%
State Street SPDR S&P Health Care Services ETF
比率0.46%
VanEck Israel ETF
比率0.14%
Humankind US Stock ETF
比率0.1%
iShares U.S. Healthcare Providers ETF
比率0.1%
Goldman Sachs Innovate Equity ETF
比率0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
比率0.05%
iShares Russell 2000 Value ETF
比率0.04%
iShares Biotechnology ETF
比率0.04%
Invesco RAFI US 1500 Small-Mid ETF
比率0.04%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
OPKO Health Incの上位5名の株主は誰ですか？
OPKO Health Incの上位5名の株主は以下のとおりです。
Frost Gamma Investments Trustは220.16M株を保有しており、これは全体の27.74%に相当します。
Rubric Capital Management LPは47.79M株を保有しており、これは全体の6.02%に相当します。
Holbrook (Bruce C)は40.38M株を保有しており、これは全体の5.09%に相当します。
The Vanguard Group, Inc.は38.16M株を保有しており、これは全体の4.81%に相当します。
Hsiao (Jane H)は33.13M株を保有しており、これは全体の4.17%に相当します。
Frost Gamma Investments Trustは220.16M株を保有しており、これは全体の27.74%に相当します。
Rubric Capital Management LPは47.79M株を保有しており、これは全体の6.02%に相当します。
Holbrook (Bruce C)は40.38M株を保有しており、これは全体の5.09%に相当します。
The Vanguard Group, Inc.は38.16M株を保有しており、これは全体の4.81%に相当します。
Hsiao (Jane H)は33.13M株を保有しており、これは全体の4.17%に相当します。
OPKO Health Incの株主タイプ上位3種は何ですか？
OPKO Health Incの株主タイプ上位3種は、
Frost Gamma Investments Trust
Rubric Capital Management LP
Holbrook (Bruce C)
Frost Gamma Investments Trust
Rubric Capital Management LP
Holbrook (Bruce C)
OPKO Health Inc（OPK）の株式を保有している機関の数はいくつですか？
2025Q3時点で、OPKO Health Incの株式を保有している機関は457社あり、保有株式の総市場価値は約208.31Mで、全体の27.13%を占めています。2025Q2と比較して、機関の持ち株は-50.75%増加しています。
OPKO Health Incの最大の収益源は何ですか？
FY2025Q2において、Health Insurers部門がOPKO Health Incにとって最大の収益を生み出しており、その金額は58.48Mで、全収益の57.84%を占めています。
